p53 mutants suppress ZBP-89 function

Anticancer Research

Volumn 26, Issue 3 A, 2006, Pages 2023-2028

  Okada, Morihiro ^a,b   Tessier, Arthur ^a   Bai, Longchuan ^a   Merchant, Juanita L ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Apoptosis; Cell cycle; Colon cancer; Etoposide; Staurosporine

Indexed keywords

ETOPOSIDE; PROTEIN P53; PROTEIN ZBP 89; STAUROSPORINE; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CELLULAR DISTRIBUTION; DIGESTIVE SYSTEM CANCER; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; MISSENSE MUTATION; PRIORITY JOURNAL; TRANSCRIPTION INITIATION;

ANIMALS; COLONIC NEOPLASMS; DNA-BINDING PROTEINS; GENES, P53; HCT116 CELLS; HUMANS; POINT MUTATION; RATS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33745632100     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Voskuil DW, Kampman E, van Kraats AA, Balder HF, van Muijen GN, Goldbohm RA and van't Veer P: p53 overexpression and p53 mutations in colon carcinomas: relation to dietary risk factors. Int J Cancer 81(5): 675-681, 1999.
2. Kobayashi S, Koide Y, Endo M, Isono K and Ochiai T: The p53 gene mutation is of prognostic value in esophageal squamous cell carcinoma patients in unified stages of curability. Am J Surg 177(6): 497-502, 1999.
3. Fox JG, Sheppard BJ, Dangler CA, Whary MT, Ihrig M and Wang TC: Germ-line p53-targeted disruption inhibits helicobacter-induced premalignant lesions and invasive gastric carcinoma through down-regulation of Th1 proinflammatory responses. Cancer Res 62(3): 696-702, 2002.
4. Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature 408(6810): 307-310, 2000.
5. Stewart ZA and Pietenpol JA: p53 Signaling and cell cycle checkpoints. Chem Res Toxicol 14(3): 243-263, 2001.
6. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88(3): 323-331, 1997.
7. Monti P, Campomenosi P, Ciribilli Y, Iannone R, Inga A, Abbondandolo A, Resnick MA and Fronza G: Tumour p53 mutations exhibit promoter selective dominance over wild-type p53. Oncogene 21(11): 1641-1648, 2001.
8. Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH et al: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84(11): 845-855, 1992.
9. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK and McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85(3): 200-206, 1993.
10. Kemp CJ, Sun S and Gurley KE: p53 induction and apoptosis in response to radio- and chemotherapy in vivo is tumor-type-dependent. Cancer Res 61(1): 327-332, 2001.
11. McIlwrath AJ, Vasey PA, Ross GM and Brown R: Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res 54(14): 3718-3722, 1994.
12. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE and Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266(5186): 807-810, 1994.
13. Merchant JL, Iyer GR, Taylor BR, Kitchen JR, Mortensen ER, Wang Z, Flintoft RJ, Michel J and Bassel-Duby R: ZBP-89, a Kruppel-like zinc finger protein, inhibits epidermal growth factor induction of the gastrin promoter. Mol Cell Biol 16: 6644-6653, 1996.
14. Wang Y, Kobori TA and Hood L: The ht beta gene encodes a novel CACCC box-binding protein that regulates T-cell receptor gene expression. Mol Cell Biol 13: 5691-5701, 1993.
15. Reizis B and Leder P: Expression of the mouse pre-T cell receptor gene is controlled by an upstream region containing a transcriptional enhancer. J Exp Med 189: 1669-1678, 1999.
16. Law GL, Itoh H, Law DJ, Mize GJ, Merchant JL and Morris DR: Transcription factor ZBP-89 regulates the activity of the ornithine decarboxylase promoter. J Biol Chem 273: 19955-19964, 1998.
17. Passantino R, Antona V, Barbieri G, Rubino P, Melchionna R, Cossu G, Feo S and Giallongo A: Negative regulation of enolase gene transcription in embryonic muscle is dependent upon a zinc finger factor that binds to the G-rich box within the muscle-specific enhancer. J Biol Chem 273: 484-494, 1998.
18. Hasegawa T, Takeuchi A, Miyaishi O, Isobe K and de Crombrugghe B: Cloning and characterization of a transcription factor that binds to the proximal promoters of the two mouse type I collagen genes. J Biol Chem 272: 4915-4923, 1997.
19. Wieczorek E, Lin S, Perkins EB, Law DJ, Merchant JL and Zehner ZE: The zinc finger repressor, ZBP-89, binds to the silencer element of the human vimentin gene and complexes with the transcriptional activator. Sp1 J Biol Chem 275: 12879-12888, 2000.
20. Ye S, Whatling C, Watkins, H and Henney A: Human stromelysin gene promoter activity is modulated by transcription factor ZBP-89. FEBS Lett 450: 268-272, 1999.
21. Bai L and Merchant JL: ZBP-89 Promotes growth arrest through stabilization of p53. Mol Cell Biol 21: 4670-4683, 2001.
22. waf1 transcription in human cells. J Biol Chem 275: 30725-30733, 2000.
23. Takeuchi A, Mishina Y, Miyaishi O, Kojima E, Hasegawa T and Isobe KI: Heterozygosity with respect to Zfp148 causes complete loss of fetal germ cells during mouse embryogenesis. Nat Genet 33: 172-176, 2003.
24. Cockell M and Gasser SM: Nuclear compartments and gene regulation. Curr Opin Genet Dev 9: 199-205, 1999.
25. Bai L, Yoon SO, King PD and Merchant JL: ZBP-89-induced apoptosis is p53-independent and requires JNK. Cell Death Differ 11: 663-673, 2004.
26. Chen GG, Merchant JL, Lai PB, Ho RL, Hu X, Okada M, Huang SF, Chui AK, Law DJ, Li YG, Lau WY and Li AK: Mutations of p53 in recurrent hepatocellular carcinoma and their association with ZBP-89 expression. Am J Pathol 162: 1823-1829, 2003.